Spots Global Cancer Trial Database for kn046
Every month we try and update this database with for kn046 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC | NCT06023758 | HER2-positive L... | KN026 KN046 XELOX | 18 Years - 75 Years | Peking University | |
| KN046 in Patients With Advanced Non-small Cell Lung Cancer | NCT03838848 | Stage IV Non-sm... | KN046 KN046 KN046 Carboplatin Pemetrexed Ningetinib | 18 Years - 75 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | NCT04469725 | Thymic Carcinom... | KN046 | 18 Years - | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| KN046 in Subjects With Advanced Solid Tumors and Lymphoma | NCT03733951 | Advanced Solid ... Lymphoma | KN046 | 18 Years - | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| Study of KN046 With Chemotherapy in First Line Advanced NSCLC | NCT04054531 | Non-small Cell ... | KN046 Paclitaxel Pemetrexed Carboplatin | 18 Years - 75 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | NCT03925870 | Esophageal Squa... | KN046 | 18 Years - 75 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer | NCT05985109 | Colorectal Canc... | KN046 regorafenib | 18 Years - | Peking University Cancer Hospital & Institute | |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC | NCT06023758 | HER2-positive L... | KN026 KN046 XELOX | 18 Years - 75 Years | Peking University | |
| KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | NCT06099821 | Digestive Syste... | KN046 Regorafenib Apatinib | 18 Years - | Peking University Cancer Hospital & Institute | |
| A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | NCT04925947 | Thymic Carcinom... | KN046 | 18 Years - | Weill Medical College of Cornell University | |
| KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | NCT03925870 | Esophageal Squa... | KN046 | 18 Years - 75 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors | NCT03529526 | Advanced Solid ... | KN046 | 18 Years - | Alphamab (Australia) Co Pty Ltd. | |
| KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | NCT05985707 | HER2-positive C... HER2-positive B... | KN026 KN046 XELOX | 18 Years - | Peking University Cancer Hospital & Institute | |
| KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor | NCT04040699 | HER2 Positive S... | KN026 combined ... | 18 Years - 75 Years | Peking University | |
| KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. | NCT05149326 | Advanced Pancre... | KN046 placebo | 18 Years - 85 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC | NCT06023758 | HER2-positive L... | KN026 KN046 XELOX | 18 Years - 75 Years | Peking University | |
| The Efficacy and Safety of KN046 Combined With Axitinib | NCT06020352 | NSCLC | KN046 plus Axit... | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer | NCT04474119 | Squamous Non-sm... | KN046 KN046 placebo | 18 Years - 75 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer | NCT05832892 | Unresectable Lo... | surufatinib KN046 gemcitabine Nab paclitaxel | 18 Years - 75 Years | Shanghai Zhongshan Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
